Unternehmensübersicht
GeoVax Labs, Inc. operates as a clinical-stage biotechnology enterprise dedicated to the development of human vaccines and immunotherapies designed to combat infectious diseases and solid tumor cancers through the application of novel proprietary platforms within the United States. The company functions within the broader healthcare sector, specifically targeting the biotechnology industry, which is characterized by high research and development expenditures and significant regulatory hurdles prior to commercial product approval. With a total market capitalization of $2.62M and an annual revenue generated over the trailing twelve months amounting to $3.35M, the firm maintains a lean operational structure supported by a workforce of 17 employees. These financial metrics indicate that GeoVax Labs, Inc. operates on a micro-cap scale with limited revenue generation relative to its sector peers, suggesting a stage focused primarily on research and development rather than mature commercialization. The combination of a market cap significantly below the multi-hundred-million-dollar threshold and revenue figures that are low relative to typical biopharma peers reflects the high-risk, pre-revenue nature of many clinical-stage entities where value is derived from intellectual property potential rather than immediate cash flow.
Finanzielle Gesundheit
Over the trailing twelve months, the company reported a revenue of $3.35M, yet simultaneously recorded a net income of $-25,309,002 and an EBITDA of $-25,469,526. The substantial discrepancy between the positive revenue of $3.35M and the negative net income exceeding $25 million reveals a cost structure where operating expenses, particularly research and development costs, vastly exceed the income generated from sales, which is typical for early-stage biotechnology firms. The free cash flow stands at $-14,961,973, indicating that the company is burning cash at a rapid pace, which limits its financial flexibility and necessitates continued access to external capital markets or private funding to sustain operations. While the gross margin is reported at 0.0%, the operating margin is even more negative at -761.6%, and the profit margin is also 0.0%, signaling that the company is not yet profitable on either a gross or bottom-line basis due to the heavy investment required to advance its vaccine candidates through clinical trials. Despite these deficits, the balance sheet shows a cash balance of $5.01M contrasted against zero debt, creating a scenario where the firm holds liquidity without leverage, though the debt-to-equity ratio is N/A due to the absence of equity or debt data in standard reporting for this specific period. The current ratio is 3.57, which suggests that the company possesses strong short-term liquidity, holding sufficient current assets to cover its current liabilities more than three times over. Furthermore, the return on equity is -377.4% and the return on assets is -178.9%, metrics that indicate management is currently destroying shareholder value in the short term as the firm prioritizes asset accumulation and clinical progress over immediate profitability.
Bewertungsanalyse
The trailing twelve-month P/E ratio is N/A due to the negative net income, while the forward P/E is reported as -1.37, a metric that implies earnings are currently negative and any future valuation based on forward earnings is theoretical until profitability is achieved. The price-to-book ratio stands at 0.29, indicating that the market values the company at significantly less than its book value, which often occurs when assets are heavily weighted towards intangible intellectual property that may not be fully reflected on the balance sheet. Alternative valuation multiples such as the price-to-sales ratio of 0.78 and an EV/EBITDA of 0.14 provide context for investors, suggesting that the market is pricing the stock at a fraction of its sales revenue and reflecting the extreme lack of earnings power inherent in the clinical-stage phase. The 52-week price range spans from a low of $1.16 to a high of $34.75, meaning the stock has experienced extreme volatility, though without a specific current share price, the exact percentage deviation from the high cannot be calculated, yet the wide range demonstrates significant price discovery challenges. The beta value is 3.81, which signifies that the stock's price volatility is nearly four times that of the broader market, exposing investors to substantial systemic risk should the overall market decline.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is insufficient data or historical performance to calculate a standard growth rate, likely due to the company's recent formation or lack of consistent reporting history. Since the earnings growth is N/A and revenue growth is N/A, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative net income of $-25,309,002 confirms that the company is not generating profits to reinvest or distribute. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, which is consistent with the strategy of retaining all earnings to fund research and development rather than paying out income to investors. Consequently, the overall growth and income profile of GeoVax Labs, Inc. is defined by a complete lack of current profitability and dividend income, relying entirely on the potential future value of its vaccine and immunotherapy pipeline to generate returns for shareholders.